| domain | evidence-based finding | suggested ontology/identifier | evidence type/strength |
|---|---|---|---|
| Disease name / aliases | RTN4IP1-related optic atrophy is a rare Mendelian mitochondrial optic neuropathy; aliases include **optic atrophy 10 (OPA10)**, **RTN4IP1-related mitochondrial disease**, and **RTN4IP1-associated optic neuropathy**. OMIM disease number repeatedly cited as **610502** in recent literature; exact MONDO/Orphanet term should be curator-verified. (pqac-00000002, pqac-00000003, pqac-00000020) | OMIM: 610502; term-name suggestions needing curator verification: “optic atrophy 10”, “RTN4IP1-related optic atrophy”, “RTN4IP1-related mitochondrial disease” | Human disease literature + recent reviews; strong for alias/OMIM, moderate for ontology cross-mapping |
| Evidence source level | Knowledge derives primarily from **aggregated disease-level literature** built from small case series/families, plus mechanistic studies in patient fibroblasts and engineered models. (pqac-00000003, pqac-00000022) | Evidence provenance annotation: human case reports/series; in vitro; model organism | Strong |
| Causal gene | The causal gene is **RTN4IP1** (reticulon 4 interacting protein 1), encoding a mitochondrial NAD(P)H oxidoreductase/OPA10-associated protein. (pqac-00000020, pqac-00000003) | HGNC gene symbol: RTN4IP1; alias: OPA10-associated gene | Strong |
| Inheritance | Reported disease mechanism is **biallelic / autosomal recessive** inheritance; consanguinity and homozygosity are recurrent in affected families, though one pathogenic allele was reported as **de novo splice** in trans with a maternally inherited missense variant. (pqac-00000003, pqac-00000009, pqac-00000011) | Inheritance term-name suggestions needing curator verification: autosomal recessive inheritance; biallelic pathogenic variants | Strong |
| Variant spectrum | Literature summarized in 2022 review/case series notes **15 single-nucleotide change mutations and 2 deletion mutations** across prior studies; variant classes include missense, truncating, splice, and deletion alleles. (pqac-00000008) | Variant class terms: missense variant; splice donor variant; truncating variant; deletion | Moderate-strong |
| Example pathogenic variants | Example disease alleles include **c.475G>T (p.Val159Phe)** founder variant in two Saudi families and **c.500C>T (p.Ser167Phe)** with **c.806+1G>A** in trans in a severe case used for mechanistic studies. (pqac-00000011, pqac-00000003) | HGVS nomenclature as reported; ClinVar/ClinGen status needs curator verification | Strong for reported families |
| Founder effect / population | A Saudi founder allele **c.475G>T (p.Val159Phe)** was estimated to have arisen ~**56 generations** (~**1400 years**) ago in two unrelated but tribally linked consanguineous families. (pqac-00000008, pqac-00000011) | Population annotation: founder variant; consanguinity-associated recessive disease | Moderate |
| Epidemiology | No robust population prevalence/incidence for RTN4IP1-specific disease was identified in the retrieved evidence; it is clearly **ultra-rare**. (pqac-00000002, pqac-00000003) | Prevalence/incidence: unknown | Strong for knowledge gap |
| Typical onset / course | Visual dysfunction and abnormalities typically **start in early childhood**; disease course is generally **progressive** and may range from isolated optic atrophy to multisystem neurologic disease. (pqac-00000009, pqac-00000003) | HPO term-name suggestions needing curator verification: childhood onset; progressive visual loss | Strong |
| Core ocular phenotype | Core ocular manifestations include **optic atrophy / optic neuropathy**, reduced visual acuity, nystagmus, photophobia, color vision impairment, optic disc pallor, central scotoma, decreased visual field sensitivity, reduced RNFL thickness, and reduced/absent VEPs. (pqac-00000009, pqac-00000022) | HPO term-name suggestions needing curator verification: optic atrophy; optic neuropathy; decreased visual acuity; nystagmus; photophobia; dyschromatopsia/color vision defect; optic disc pallor; central scotoma; visual field defect; decreased retinal nerve fiber layer thickness; abnormal visual evoked potential | Strong |
| Ocular phenotype severity spectrum | Spectrum spans **isolated optic atrophy** to **optic atrophy with rod-cone/retinal dystrophy** and to syndromic neuro-ophthalmic disease; recent literature notes retinal dystrophy as a bona fide expansion of phenotype. (pqac-00000008, pqac-00000003) | HPO term-name suggestions needing curator verification: rod-cone dystrophy; retinal dystrophy | Moderate |
| Neurologic phenotypes | Frequent extraocular findings include **developmental delay/intellectual disability**, **encephalopathy**, **ataxia/unsteady gait**, and **seizures**; severe cases may lose ambulation. (pqac-00000007, pqac-00000010, pqac-00000011) | HPO term-name suggestions needing curator verification: developmental delay; intellectual disability; encephalopathy; ataxia; gait disturbance; loss of ambulation; seizures; generalized tonic-clonic seizures | Strong |
| Additional systemic findings | Muscle biopsy may show **ragged-red-like fibers**, subsarcolemmal mitochondrial accumulation, COX/SDH abnormalities, and increased neutral lipid stores; MRS may show a **small lactate peak**. Dysmorphic features and eczema were noted in at least one patient. (pqac-00000007, pqac-00000010) | HPO / pathology term-name suggestions needing curator verification: ragged-red muscle fibers; lactic acid peak on MRS; eczema; dysmorphic facies | Moderate |
| Brain / neuroimaging findings | Brain MRI in the Saudi cohort showed **optic nerve/chiasm atrophy**; MRS demonstrated **small lactate doublets** in several patients, supporting metabolic dysfunction. (pqac-00000007) | UBERON term-name suggestions needing curator verification: optic nerve; optic chiasm; brain; HPO suggestions: optic nerve atrophy; elevated lactate peak on MRS | Strong within one cohort |
| Primary anatomy affected | The primary affected structure is the **optic nerve**, with disease conceptually centered on **retinal ganglion cell (RGC)** degeneration in inherited optic neuropathies. (pqac-00000016, pqac-00000013) | UBERON term-name suggestions needing curator verification: optic nerve; retina; retinal nerve fiber layer; optic chiasm | Strong for optic nerve, moderate for RTN4IP1-specific RGC inference |
| Cell types implicated | Vulnerable cells are inferred to be **retinal ganglion cells** and likely their axons within the papillomacular bundle, as for mitochondrial optic neuropathies generally; neuronal cells and astrocytes show RTN4IP1 immunoreactivity in tissue-expression data cited in RTN4IP1 literature. (pqac-00000016, pqac-00000008) | CL term-name suggestions needing curator verification: retinal ganglion cell; astrocyte; neuron | Moderate |
| Subcellular localization | RTN4IP1 localizes to the **mitochondrial matrix**; disease mechanisms implicate the **inner mitochondrial membrane respiratory-chain system**, CoQ pool, and supercomplex assembly. (pqac-00000020, pqac-00000021, pqac-00000004) | GO cellular component term-name suggestions needing curator verification: mitochondrial matrix; mitochondrial inner membrane; respiratory chain complex I; mitochondrial respiratory chain supercomplex | Strong |
| Central molecular mechanism 1 | RTN4IP1 is a **mitochondrial NAD(P)H oxidoreductase** essential for **coenzyme Q (CoQ) biosynthesis**, likely supporting COQ3-dependent O-methylation steps; RTN4IP1 loss decreases CoQ9/CoQ10 and impairs respiration. (pqac-00000020, pqac-00000003, pqac-00000018) | GO term-name suggestions needing curator verification: coenzyme Q biosynthetic process; oxidoreductase activity; mitochondrial electron transport | Strong |
| Central molecular mechanism 2 | RTN4IP1 is also a **late-stage complex I assembly factor**. Complexome profiling showed **accumulation of unincorporated ND5-module**, **impaired N-module production**, reduction of CI-containing supercomplexes, and isolated CI defects. (pqac-00000002, pqac-00000004, pqac-00000005) | GO term-name suggestions needing curator verification: mitochondrial respiratory chain complex I assembly; oxidative phosphorylation; respiratory chain supercomplex assembly | Strong (2024 mechanistic study includes patient fibroblasts + knockout cells, but preprint) |
| Central molecular mechanism 3 | RTN4IP1 deficiency increases **oxidative stress/ROS-associated damage**, with higher 8-oxo-dG nuclear foci, cristae collapse, outer-membrane rupture, vacuolation, and autophagy-related multilamellar bodies in knockout cells. (pqac-00000018) | GO term-name suggestions needing curator verification: response to oxidative stress; reactive oxygen species metabolic process; mitophagy/autophagy; mitochondrial cristae organization | Strong for model-cell evidence |
| Functional consequence | The net functional consequence is predominantly **loss of function**, with marked reduction or absence of RTN4IP1 protein in patient fibroblasts for severe alleles and impaired oxidative phosphorylation. (pqac-00000008, pqac-00000003) | Molecular consequence annotation: loss of function; decreased protein stability | Strong |
| Upstream-to-downstream causal chain | Biallelic RTN4IP1 pathogenic variants → decreased/absent RTN4IP1 protein or dysfunctional oxidoreductase → impaired CoQ biosynthesis and late CI assembly → reduced mitochondrial respiration / membrane potential and oxidative stress → selective vulnerability of optic nerve/RGC system ± brain/muscle involvement → optic atrophy, visual loss, developmental neurologic syndrome. (pqac-00000003, pqac-00000004, pqac-00000018, pqac-00000022) | GO process set needing curator verification: complex I assembly; CoQ biosynthesis; oxidative phosphorylation; response to oxidative stress; neuron death | Strong integrated mechanistic inference |
| Biochemical abnormalities | Reported biochemical signatures include **isolated complex I deficiency** in muscle/patient cells, prior reports of **complex I and IV defects** in fibroblasts, decreased CoQ10, increased **PPHB10** intermediate, and reduced oxygen consumption/ATP production in models. (pqac-00000009, pqac-00000003, pqac-00000020) | CHEBI term-name suggestions needing curator verification: coenzyme Q10; PPHB10; GO: ATP biosynthetic process/oxidative phosphorylation | Strong |
| Diagnostics: clinical ophthalmic | Diagnostic workup may show bilateral optic atrophy, nystagmus, optic disc pallor, reduced RNFL thickness on OCT, central scotoma/visual field loss, and reduced or absent visual evoked potentials. (pqac-00000009, pqac-00000022) | Test annotations needing curator verification: OCT RNFL analysis; visual field testing; VEP | Strong |
| Diagnostics: neuro/metabolic | Supportive findings can include brain MRI evidence of optic pathway atrophy and MRS lactate peaks; standard metabolic screens may be normal in some patients, so absence of classic metabolic abnormalities does not exclude disease. (pqac-00000007, pqac-00000010) | MRI/MRS; lactate peak; metabolic evaluation | Moderate |
| Diagnostics: pathology | Muscle biopsy can reveal mitochondrial myopathy-type changes including ragged-red-like fibers, subsarcolemmal mitochondrial accumulation, SDH/COX staining abnormalities, and lipid accumulation. (pqac-00000007, pqac-00000010) | Pathology term-name suggestions needing curator verification: ragged-red fibers; abnormal SDH stain; abnormal COX stain; lipid storage myopathy features | Moderate |
| Diagnostics: genetic testing | **WES/WGS/panel testing** are appropriate because RTN4IP1 is one of many genes causing hereditary optic neuropathy, particularly with pediatric onset or syndromic features; segregation and, where needed, functional follow-up strengthen interpretation. (pqac-00000009, pqac-00000016, pqac-00000003) | Testing strategy suggestions: hereditary optic neuropathy gene panel; exome sequencing; genome sequencing; Sanger segregation | Strong |
| Differential diagnosis context | RTN4IP1-related disease belongs within the differential of **hereditary optic neuropathies** and **mitochondrial optic neuropathies**, alongside OPA1/DOA, LHON, TMEM126A, WFS1, and other nuclear mitochondrial disorders. (pqac-00000013, pqac-00000016) | Disease-group ontology suggestions needing curator verification: hereditary optic neuropathy; mitochondrial disease; optic nerve disorder | Strong for disease-group placement |
| Management: disease-specific evidence | No RTN4IP1-specific disease-modifying therapy was identified in the retrieved clinical-trial search; management remains primarily **supportive and surveillance-based**. (pqac-00000016, pqac-00000013) | NCIT term-name suggestions needing curator verification: supportive care; low vision rehabilitation; multidisciplinary surveillance | Strong for current practice gap |
| Management: supportive ophthalmic | Practical care extrapolated from inherited mitochondrial optic neuropathies includes **low-vision aids**, educational accommodations, visual rehabilitation, and ophthalmic follow-up. (pqac-00000013, pqac-00000016) | NCIT term-name suggestions needing curator verification: low vision rehabilitation; assistive device; ophthalmologic monitoring | Moderate (extrapolated, not RTN4IP1-specific trial evidence) |
| Management: neurologic / systemic | Syndrome-directed care includes seizure management, developmental/rehabilitation support, gait/mobility aids, and screening for multisystem involvement as clinically indicated. (pqac-00000010, pqac-00000016) | NCIT term-name suggestions needing curator verification: anticonvulsant therapy; physical therapy; occupational therapy; developmental support | Moderate |
| CoQ supplementation | Mechanistic/model evidence suggests **CoQ analog supplementation can partially rescue** respiratory or locomotor phenotypes in model systems, but robust human RTN4IP1 treatment evidence is lacking in retrieved sources. (pqac-00000018, pqac-00000004) | CHEBI/NCIT term-name suggestions needing curator verification: coenzyme Q; ubiquinone supplementation | Moderate for preclinical rationale, weak for human efficacy |
| Idebenone | **Idebenone is approved for LHON**, not for RTN4IP1-related optic atrophy; any use in RTN4IP1 would be extrapolative/off-label absent direct evidence. (pqac-00000016, pqac-00000013) | Drug annotation: idebenone; indication-specific note: LHON-approved, not RTN4IP1-specific | Strong for distinction |
| Clinical trials | The retrieved ClinicalTrials.gov-style search found **no RTN4IP1-specific interventional trial**. (pqac-00000000) | Trial status: none identified | Moderate-strong |
| Prognosis | Prognosis is **variable**: some patients have isolated visual disease, while others develop severe childhood-onset neurodevelopmental impairment, ataxia, epilepsy, and loss of ambulation. Quantitative survival data are not established in the retrieved evidence. (pqac-00000003, pqac-00000007, pqac-00000011) | Prognosis annotation: variable expressivity; pediatric-onset progressive disorder | Strong for variability, weak for survival statistics |
| Animal / cellular models | Available models include **patient fibroblasts**, **CRISPR RTN4IP1 knockout U2OS cells**, **Rtn4ip1-knockout C2C12 myoblasts**, **Drosophila dRTN4IP1 knockdown**, and literature-cited **mouse and zebrafish depletion models** from the original discovery era. (pqac-00000003, pqac-00000018, pqac-00000015) | Model system annotations: human fibroblast model; U2OS KO; C2C12 KO; Drosophila RNAi; mouse model; zebrafish morphant/model | Strong for cell/fly models; moderate for early vertebrate models from review citation |
| Model phenotypes | Models recapitulate impaired respiration, reduced CoQ, mitochondrial ultrastructural damage, lethality with strong depletion, and locomotor/muscle defects; fly muscle phenotypes improved with dietary CoQ2. Reviews cite early mouse/zebrafish depletion as relevant to retinal/RGC pathology, but exact primary-model details were not directly retrievable here. (pqac-00000018, pqac-00000015) | Phenotype annotations needing curator verification: mitochondrial dysfunction; motor impairment; retinal developmental defect/RGC loss | Strong for fly/cell, moderate for vertebrate ocular models |
| Omics / advanced profiling | Recent mechanistic work used **targeted lipidomics**, **proteomics**, **blue-native electrophoresis**, and **complexome profiling**; PRIDE dataset identifier reported as **PXD055511** in preprint methods. (pqac-00000005, pqac-00000003) | PRIDE: PXD055511; assay terms needing curator verification: lipidomics; complexome profiling; BN-PAGE | Strong |
| Environmental risk / protective factors | No RTN4IP1-specific environmental modifiers are established in retrieved human evidence. General mitochondrial optic-neuropathy advice about avoiding oxidative stressors (e.g., smoking/toxins) is **extrapolated** rather than RTN4IP1-specific. (pqac-00000016, pqac-00000013) | Environmental modifier status: unknown for RTN4IP1-specific disease | Strong for evidence gap |
| Gene–environment interaction | No direct RTN4IP1-specific gene–environment interaction data were identified. (pqac-00000016) | Unknown / not established | Strong for knowledge gap |
| Protective genetic factors / modifier genes | No validated RTN4IP1-specific protective variants or modifier genes were identified in the retrieved evidence. (pqac-00000003, pqac-00000022) | Unknown / not established | Strong for knowledge gap |
| Epigenetics | No disease-specific DNA methylation, chromatin, or histone-mark evidence for RTN4IP1-related optic atrophy was identified in the retrieved sources. | Unknown / not established | Strong for knowledge gap |
| Chromosomal abnormalities | Small intragenic deletions have been reported in the broader literature, but no recurrent large chromosomal abnormality defines the disorder in retrieved evidence. (pqac-00000008) | Structural variant annotation: possible intragenic deletion; curator verification needed | Weak-moderate |
| Ontology curation note | Many exact HPO/GO/UBERON/CL/NCIT IDs were not directly confirmed in the retrieved context and should be **curator-verified before database loading**. | Curation status flag: needs ontology ID verification | Strong |


*Table: This table condenses the main disease-characteristics evidence for RTN4IP1-related optic atrophy into a knowledge-base-friendly format. It highlights what is directly supported by human and mechanistic studies, what is extrapolated from related mitochondrial optic neuropathies, and where ontology or evidence gaps remain.*